Nifty Next 50Healthcarenifty next 50
Divi's Laboratories Share Price & Analysis
Divi's Labs is a global leader in custom synthesis and API manufacturing.
Live price
DIVISLAB · Healthcare
₹9,322.00
−116.50 (−1.23%)
Day High
₹9,415.00
Day Low
₹9,310.50
52W High
₹9,615.00
52W Low
₹5,636.50
Volume today: 5.17 L
Key fundamentals
Market cap
—
P/E ratio
—
P/B ratio
—
ROE
—
Debt / Equity
—
Dividend yield
—
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
BUYScore 72/100 · Medium confidence
Overall fundamentals and market signals are favourable. Consider for long-term portfolios with periodic review.
12M Price Target
₹10,254
Low ₹9,136 · High ₹11,653
Analyst-style Breakdown
Strong Buy
0
Buy
4
Hold
12
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum95/100
1M +8.4%, 1Y +55.6%
Earnings Trend92/100
Latest quarter revenue ₹3.1k Cr, profit ₹902 Cr
Valuation50/100
P/E — vs sector median ~35x
Financial Quality28/100
ROE —, ROCE —
Technical Position72/100
Trading between 52W low 5637 and high 9615
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹3.1k Cr | ₹902 Cr | ₹33.95 | +19.1% | +36.3% |
| Mar 2026 | ₹2.8k Cr | ₹751 Cr | ₹28.31 | — | — |
| Dec 2025 | ₹2.6k Cr | ₹583 Cr | ₹21.98 | — | — |
| Jun 2025 | ₹2.4k Cr | ₹545 Cr | ₹20.49 | — | — |
| Mar 2025 | ₹2.6k Cr | ₹662 Cr | ₹24.93 | — | — |
Reference Ratios
Market Capⓘ
—
P/E Ratioⓘ
—
P/B Ratioⓘ
—
ROEⓘ
—
ROCEⓘ
—
Div Yieldⓘ
—
Company Overview
Manufactures APIs and intermediates for innovator and generic pharma customers worldwide.
Strengths
- + High-margin custom synthesis relationships
- + Scale in API manufacturing
Risks
- − Customer concentration in key molecules
- − Regulatory inspection and compliance risk
Latest News
No recent news articles for Divi's Laboratories yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Divi's Laboratories is a current constituent of the Nifty Next 50, which represents the 50 largest Nifty 100 companies outside the Nifty 50.